Inventor · disambiguated record
Michelle Kuhne
Also filed as: KUHNE MICHELLE · KUHNE MICHELLE R · KUHNE MICHELLE RENNE
11 granted patents·11 pending applications·59 citations·filing 2007–2025
88Inventor score
Files withBRISTOL MYERS SQUIBB CO13GILEAD SCIENCES INC5SQUIBB & SONS LLC2KUHNE MICHELLE1OXFORD BIOTHERAPEUTICS LTD1
Top patents by PatentIndex Score
22 records- 0195US11124582B2FLT3L-FC fusion proteinsGILEAD SCIENCES INC·Filed 2020·Granted Sep 21, 2021·16 cites·1 claims
- 0294US12312403B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2023·Granted May 27, 2025·1 cites·17 claims
- 0394US10077306B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Sep 18, 2018·7 cites·22 claims
- 0493US10533052B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jan 14, 2020·4 cites·30 claims
- 0590US8450464B2Human monoclonal antibodies that bind CXCR4KUHNE MICHELLE·Filed 2007·Granted May 28, 2013·24 cites·42 claims
- 0687US2024209083A1Antibodies against tim3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 0786US11591392B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Feb 28, 2023·1 cites·19 claims
- 0880US9932411B2AntibodiesOXFORD BIOTHERAPEUTICS LTD·Filed 2014·Granted Apr 3, 2018·5 cites·24 claims
- 0978US2024174749A1Methods of treating cancer with antibodies against tim3BRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 1076US2025326841A1Antibodies against tim3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2025·Application pending·0 cites
- 1176US2025115664A1Antibodies against tim3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 1270US10428151B2Treatment of hematologic malignancies with an anti-CXCR4 antibodyBRISTOL MYERS SQUIBB CO·Filed 2012·Granted Oct 1, 2019·1 cites·25 claims
- 1368US2025197494A1Methods of treating cancer with antibodies against tim3BRISTOL MYERS SQUIBB CO·Filed 2025·Application pending·0 cites
- 1466US2022049021A1FLT3L-Fc FUSION PROTEINS AND METHODS OF USEGILEAD SCIENCES INC·Filed 2021·Application pending·0 cites
- 1564US2020231683A1Treatment of hematologic malignancies with an anti-cxcr4 antibodyBRISTOL MYERS SQUIBB CO·Filed 2019·Application pending·0 cites
- 1662US12129297B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Oct 29, 2024·0 cites·10 claims
- 1762US2021009718A1FLT3L-Fc FUSION PROTEINS AND METHODS OF USEGILEAD SCIENCES INC·Filed 2020·Application pending·0 cites
- 1861US2021363242A1Methods of treating cancer with antibodies against tim3BRISTOL MYERS SQUIBB CO·Filed 2019·Application pending·0 cites
- 1960US2022389394A1METHODS OF USING FLT3L-Fc FUSION PROTEINSGILEAD SCIENCES INC·Filed 2022·Application pending·0 cites
- 2059US11312777B2Human monoclonal antibodies that bind CXCR4 and uses thereofSQUIBB & SONS LLC·Filed 2018·Granted Apr 26, 2022·0 cites·24 claims
- 2159US10106615B2Nucleic acids encoding human monoclonal antibodies that bind CXCR4SQUIBB & SONS LLC·Filed 2013·Granted Oct 23, 2018·0 cites·13 claims
- 2256US2024165227A1Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinationsGILEAD SCIENCES INC·Filed 2023·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →